ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCAâs lead development program is intended to be a direct implementation of those ideas. Gencaro⢠(bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF) in patients with a specific type of heart failure (HF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaroâ˘, giving Gencaro⢠the potential to be the first genetically-targeted prevention treatment for AF. AF is considered to be an epidemic cardiovascular disease and AF therapies that are safe and effective for patients with heart failure is considered a major unmet medical need. The approved therapies for the treatment or prevention AF have certain disadvantages in heart failure patients, such as toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contraindicated or have warnings in their prescribing information for such patients. We believe there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in heart failure patients. Source
No articles found.
Natus is a leading provider of healthcare products and services used for the scree...
Natus is a leading provider of healthcare produ...
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device compan...
Cardiovascular Systems, Inc., based in St. Paul...
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on ap...
InflaRx (Nasdaq: IFRX) is a clinical-stage biop...
St. Renatus, LLC, named after the patron saint of anesthesia, is a privately held ...
St. Renatus, LLC, named after the patron saint ...
At MannKind Corporation (NASDAQ: MNKD), we focus on the discovery, development and...
At MannKind Corporation (NASDAQ: MNKD), we focu...
Albireo is a clinical-stage biopharmaceutical company focused on the development a...
Albireo is a clinical-stage biopharmaceutical c...
Dicerna is a biopharmaceutical company focused on the discovery and development of...
Dicerna is a biopharmaceutical company focused ...
Join the National Investor Network and get the latest information with your interests in mind.